Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications

Abstract

A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.

What is claimed is: 
     
         1 . A method of promoting wound healing or connective tissue reconstruction in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm 2  tissue of Erythropoietin and about 100-300 μg per cm 2  tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction in the subject. 
     
     
         2 . A method of treating ischemia in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm 2  tissue of Erythropoietin and about 100-300 μg per cm 2  tissue of Fibronectin, thereby treating ischemia in the subject. 
     
     
         3 . The method of  claim 1 , wherein the connective tissue comprises collagen. 
     
     
         4 . The method of  claim 1 , wherein a dose of said Erythropoietin is about 20 μg per cm 2  tissue. 
     
     
         5 . The method of  claim 1 , wherein a dose of said Fibronectin is about 200 μg per cm 2  tissue. 
     
     
         6 . The method of  claim 1 , further comprising administering a factor selected from the group consisting of an extracellular matrix component, a growth factor, a hormone, an angiogenic factor, a coagulation factor, a cytokine, a chemokine, an enzyme, a neurotransmitter, a vitamin, a carbohydrate, an ion, an iron chelator, a fatty acid, an antibiotic, and an amino acid. 
     
     
         7 . The method of  claim 1 , wherein said administering of said Erythropoietin and said Fibronectin is effected concomitantly. 
     
     
         8 . The method of  claim 1 , wherein said Erythropoietin and said Fibronectin are in a co-formulation. 
     
     
         9 . The method of  claim 1 , wherein said Erythropoietin and said Fibronectin are in separate formulations. 
     
     
         10 . The method of  claim 2 , wherein a dose of said Erythropoietin is about 20 μg per cm 2  tissue. 
     
     
         11 . The method of  claim 2 , wherein a dose of said Fibronectin is about 200 μg per cm 2  tissue. 
     
     
         12 . The method of  claim 2 , further comprising administering a factor selected from the group consisting of an extracellular matrix component, a growth factor, a hormone, an angiogenic factor, a coagulation factor, a cytokine, a chemokine, an enzyme, a neurotransmitter, a vitamin, a carbohydrate, an ion, an iron chelator, a fatty acid, an antibiotic, and an amino acid. 
     
     
         13 . The method of  claim 2 , wherein said administering of said Erythropoietin and said Fibronectin is effected concomitantly. 
     
     
         14 . The method of  claim 2 , wherein said Erythropoietin and said Fibronectin are in a co-formulation. 
     
     
         15 . The method of  claim 2 , wherein said Erythropoietin and said Fibronectin are in separate formulations. 
     
     
         16 . The method of  claim 1 , wherein the active ingredients administered to said subject consist of Erythropoietin and Fibronectin. 
     
     
         17 . The method of  claim 1 , wherein said administering is effected at least once a day. 
     
     
         18 . A pharmaceutical composition comprising as an active ingredient about 10-30 μg per ml Erythropoietin and about 100-300 μg per ml Fibronectin and a pharmaceutically acceptable carrier or diluent for topical administration.